NasdaqCM - Nasdaq Real Time Price ? USD TC Biopharm (Holdings) Plc (TCBPW) Follow Compare 0.0302 0.0000 (0.00%) At close: October 17 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the patient screening process. PR Newswire ? 17 days ago TCBP TCBPW 0.00% TCBP Announces Site Opening of Guys and St. Thomas Hospital TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced new site opening of Guys and St. Thomas Hospital in the ACHIEVE UK Trial. PR Newswire ? 25 days ago TCBP TCBPW 0.00% TCBP to Present at the 2024 ThinkEquity Conference in NYC TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer Bryan Kobel has been invited to present at the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York City. PR Newswire ? 26 days ago TCBP TCBPW 0.00% /C O R R E C T I O N -- TC BioPharm/ TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients. As previously stated, patients are eligible to receive up to 4 total doses of TCB under the ACHIEVE PR Newswire ? 30 days ago TCBP TCBPW 0.00% TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients. As previously stated, patients are eligible to receive up to 4 total doses of TCB under the ACHIEVE PR Newswire ? last month TCBP TCBPW 0.00% TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox. PR Newswire ? last month TCBP TCBPW 0.00% TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications today announced it will participate at the H.C. Wainwright 26th Annual Global Investment Conference from September 9–11, 2024 in New York City. PR Newswire ? last month TCBP TCBPW 0.00% Sector Update: Health Care Stocks Decline Late Afternoon Sector Update: Health Care Stocks Decline Late Afternoon PREMIUM MT Newswires ? last month TCBPW 0.00% PCVX TCBP Announces Dosing of 5 New Patients in ACHIEVE TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces dosing of 5 new patients in the ACHIEVE Phase 2b trial ongoing in the UK. PR Newswire ? last month TCBP TCBPW 0.00% TC BioPharm secures European patent for cancer treatment TCBP earmarked the net proceeds from the offering to support key initiatives. Pharmaceutical Technology ? last month TCBPW 0.00% TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering, upsized to 6,000,000 shares of its American Depository Shares ("ADSs")(or pre-funded warrants in lieu thereof), together with Series H warrants ("Series G Warrants") to purchase up to 6,000,000 ADSs at a combined public PR Newswire ? last month TCBP TCBPW 0.00% TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has received a patent grant from European Patent Office (EPO) covering the use of modified gamma delta cells for the treatment of cancer and viral indications. PR Newswire ? last month TCBP TCBPW 0.00% TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b) TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the Company has regained compliance with the Nasdaq Stock Market Listing Rule 5550(b) which will maintain the listing of the Company's American depositary shares on the Nasdaq Global Select Market. PR Newswire ? 2 months ago TCBP TCBPW 0.00% TC BioPharm Announces Closing of $2.0 Million Public Offering TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering of 2,000,000 shares of its American Depository Shares ("ADSs")(or pre-funded warrants in lieu thereof), together with Series G warrants ("Series G Warrants") to purchase up to 2,000,000 ADSs at a combined public offering PR Newswire ? 2 months ago TCBP TCBPW 0.00% TC BioPharm Announces Pricing of $2.0 Registered Direct Offering TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into definitive agreement for the purchase and sale of 2,000,000 shares of its American Depository Shares and Pre-Funded Warrants at an offering price of $1 per share in a registered direct offering and an additional 2,000,000 cash exercise only Series G warran PR Newswire ? 2 months ago TCBP TCBPW 0.00% TCBP Announces Plan to Implement ADS Ratio Change TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will change its ratio of its American Depositary Shares ("ADSs") to ordinary shares from one (1) ADS representing twenty (20) ordinary shares to one ADS representing two hundred (200) ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become PR Newswire ? 2 months ago TCBP TCBPW 0.00% TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on July 16, the sixth patient in ACHIEVE (UK) was treated. This is the first patient treated with a higher dose of TCB-008 post the amendment approved by the MHRA on Feb 22, 2024. PR Newswire ? 2 months ago TCBP TCBPW 0.00% TCBP Announces Launch of Compassionate Use Program for TCB008 TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK. PR Newswire ? 5 months ago TCBP TCBPW 0.00% TC BioPharm Announces Exercise of Warrants for ￡3.1 Million Gross Proceeds TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company's American Depositary Shares (the "ADSs") originally issued in December 2023 with an exercise price of ￡1.5814 per ADS and a term of five yea PR Newswire ? 5 months ago TCBP TCBPW 0.00% TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors. PR Newswire ? 5 months ago TCBP TCBPW 0.00%
